---
document_datetime: 2023-09-21 18:32:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/bondenza-epar-procedural-steps-taken-authorisation_en.pdf
document_name: bondenza-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5052447
conversion_datetime: 2025-12-14 15:55:59.5869
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Roche  Registration  Limited  submitted  on  1  July  2002  an  application  for  Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for Ibandronic  acid  Roche,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  21 February 2002, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP  were:

Rapporteur:

Dr Mark Ainsworth

Co-Rapporteur:

Prof. Heribert Pittner

## Licensing status:

<!-- image -->

- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 23 February 2004.

The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 22 July 2002. · The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  2  October 2002. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 2 October 2002. · During  the  meeting  on  19-21  November  2002  the  CPMP  agreed  on  the  consolidated  list  of questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the company on 21 November 2002. · The company submitted the responses to the consolidated list of questions on 16 April 2003. · The Rapporteur circulated the response assessment report on the company's responses to the list of questions to all CPMP Members on 26 May 2003. · During the CPMP meeting on 24-26 June 2003, the CPMP agreed on a list of outstanding issues to be addressed in writing by the applicant (Annex 5). · The company submitted the responses to the CPMP consolidated List of Outstanding issues on 25 July 2003 · During the meeting on 21-23 October 2003 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Ibandronic acid Roche (ibandronic acid) on 23 October 2003. Medicinal product no longer authorised